Catalyst Dossier · compiled by CeliA 🧫

BeOne Medicines Ltd. (BEIGF)

Biotechnology · market cap $40.9B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-22 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

BeOne Medicines Ltd. (BEIGF) is a global biotechnology company with approximately 11,000 employees and a market capitalization of roughly $40.9 billion. The company's pipeline is anchored by zanubrutinib (BTK inhibitor, approved in CLL and other B-cell malignancies) and sonrotoclax (Phase 3 in Waldenstrom Macroglobulinemia), with BGB-16673 in Phase 2 for B-cell malignancies. Key binary readouts are clustered in Q3–Q4 2026.

The catalyst path

2026-09-22 (est.)Phase 2 · Sonrotoclaximp 7/10
2026-11-15 (est.)Phase 2 · BGB-16673imp 7/10

Pipeline

Asset	Phase	Indication
BGB-16673	Phase 2	B-cell Malignancy
Sonrotoclax	Phase 3	Waldenstrom Macroglobulinemia
Zanubrutinib	Phase 3	Chronic Lymphocytic Leukemia

Price & technical context

3-month

+58.6%

6-month

+58.6%

12-month

+63.2%

52-wk range

$13.68–$25.29

vs 50-day MA

+22.7%

vs 200-day MA

+47.3%

Realized vol

58.9%

Max drawdown

-23.0%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BEIGF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.